| abstract |
The present invention relates to a liquid formulation comprising a cosolvent and Montelukast or a pharmaceutically acceptable salt thereof as an active ingredient in a solution state, and a process for the preparation thereof. The liquid formulation of the present invention allows Montelukast or a pharmaceutically acceptable salt thereof to be substantially dissolved and present in a solution state, thereby preventing dissolution from decreasing over time and increasing its bioavailability. Further, since the liquid formulation of the present invention exhibits excellent stability, taste and taste, the medication compliance can be increased and it can be effectively used in patients with asthma and allergic rhinitis. |